
AstraZeneca has signed an agreement to develop and commercialise a cancer nanomedicine from US firm Bind Therapeutics’ stable of Accurins. …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

